Purpose. The purpose of this study was to evaluate efficacy of multislice computed tomography (MSCT) and single photon emission computed tomography (SPECT)-CT with Tc-99m Sestamibi in the assessment of solitary pulmonary nodules of uncertain significance. Scintigraphy was performed using a 'hybrid' g-camera that allows simultaneous acquisition of SPECT and CT images, with interesting results in diagnostic oncology.
Introduction
Diagnostic imaging has achieved important results in the evaluation of solitary pulmonary nodules (SPNs) with multislice computed tomography (MSCT), thanks to major technological advances. This technique can now perform thinslice imaging of the lung parenchyma, and it employs software providing information on size, volume, density and contrast enhancement of pulmonary nodules as well as calculating automatically and accurately any change in size by comparing studies conducted at different times.
A few nodules can be defined as probably benign (presence of fat or benign calcification) and not requiring further investigation; others are highly suspicious for malignancy (spiculated margins, malignant calcification, diameter >2 cm) and require immediate surgical excision or biopsy [1] . The majority of pulmonary nodules (70%), however, cannot be characterised with certainty, even after a CT scan.
Encouraging results in lung cancer diagnosis have been obtained with single photon emission computed tomography (SPECT) using 99mTc-hexakis-2-methoxy-isobutyl-isonitrile (Sestamibi), a lipophilic cation used in myocardial perfusion scintigraphy [2] [3] [4] .
This technique currently makes use of new devices equipped with an X-ray tube-detector system for CT scans. Scintigraphy is carried out using a 'hybrid' g-camera allowing acquisition of SPECT and CT images during the same session. Preliminary results of the clinical application of this new diagnostic tool in the study of different neoplasms, including thoracic applications, have been very interesting [5, 6] . This allows for a more effective and accurate preclinical diagnosis of disease, given that the early diagnosis of lung cancer is still the only means to improve patient survival [7, 8] .
Our study investigated the characterisation of solitary nodules of uncertain significance discovered at chest radiography or incidentally during CT by integrating scintigraphy with MSCT. Our aim was to correlate the results of MSCT and Sestamibi SPECT-CT in the early diagnosis of lung cancer and to assess their concordance with histological examination.
Materials and methods
Between September 2003 and August 2004, we selected 23 patients (17 men and six women) aged between 40 and 82 years (mean age 63.2) with an SPN ranging from 0.8 cm to 2 cm in size (mean size 1.3 cm) discovered at CT performed to investigate a chest radiography finding or as a diagnostic examination for another condition.
Our study excluded nodules with tomodensitometric characteristics highly suggestive of either benign or malignant disease. The examinations were conducted with a LightSpeed 16 MSCT scanner (GE Medical Systems, Milwaukee, WI, USA) capable of obtaining slice thicknesses between 10 mm and 0.625 mm. The examination was performed dur- [5, 6] . Tutto ciò ci consente di fare una diagnosi pre-clinica di malattia molto più efficace e accurata, dato che la diagnosi precoce delle neoplasie del polmone rimane l'unico mezzo per aumentare la sopravvivenza dei pazienti affetti [7, 8] .
Introduzione

La diagnostica per immagini ha raggiunto, grazie agli imponenti progressi tecnologici, importanti risultati nella valutazione del nodulo polmonare solitario (NPS) con l'ausilio della tomografia computerizzata multistrato (TCms
Il ing a single breathhold before and after administration of nonionic iodinated contrast material (80-100 ml, 3-4 ml/s flow rate, 25-30 s delay after starting the administration). Informed consent was obtained from all patients.
Acquisition parameters were as follows: slice thickness 5 mm (back reconstruction up to 0.625 mm), feed 11.25 mm/rotation, rotation time 0.5 s, total acquisition time 12-15 s, 120-140 kV, 200-240 mA. Images were processed on an Advantage W 4.1 workstation supplied by the same company using multiplanar reconstructions (MPR), volume rendering (VR) and automatic segmentation software (ALA), which provides an accurate assessment of size, shape and density once the operator has selected the region of interest and performed three-dimensional (3D) segmentation with removal of adjacent structures.
Volume and morphology data obtained at the first measurement were compared with those of the follow-up examinations. Risk assessment was not performed on 2D criteria, such as changes in lesion diameter, but on 3D criteria, so that when the volume doubles, the lesion diameter actually increases by only 26%.
All patients then underwent (within 5 days) lung scintigraphy with positive indicator using a VG Millennium (GE Medical Systems) dual-head gamma camera equipped with an X-ray tube-detector system similar to a third-generation CT [9] . This 'hybrid' system has shown to improve the diagnostic accuracy of a large number of SPECT examinations [5] .
Twenty minutes after the IV administration of about 740 MBq of Tc-99m Sestamibi, SPECT-CT of the chest was performed. A total of 120 planar images (one every 3°) lasting 25 s each were acquired on a rotation arc of 360°using a 128x128 matrix. Immediately afterwards, without moving the patient from the gamma camera bed, a low-resolution chest CT was done, with a field of view of 40 cm, exactly equal to that of the SPECT acquisition.
Parameters used in this CT are fixed and cannot be changed by the operator: slice thickness 1 cm, acquisition time approximately 14 s per section, 140 kV and 2.5 mA. The SPECT and CT images were processed with a dedicated workstation (Integra, GE Medical Systems), enabling rapid and accurate fusion of the relevant sections of the functional (SPECT) and anatomical (CT) studies.
In particular, SPECT images were processed using the method of filtered backprojections. After prefiltering with a Metz filter, the SPECT images were reconstructed in a ramp filter in order to produce transaxial sections from which coronal and sagittal images were derived.
Patients with positive nodules at scintigraphy underwent invasive procedures for histological characterisation (CTguided or bronchoscopic biopsy, video-assisted thoracoscopic excision).
Patients with negative nodules at scintigraphy underwent repeat CT after 3-4 months with reassessment of volume by means of ALA software and subsequent histological characterization (CT-guided or bronchoscopic biopsy, video-assisted thoracoscopic excision).
In these cases, follow-up CT was always performed with the same acquisition parameters as the first examina- [9] . Questo sistema "ibrido" si è rivelato utile per aumentare l'accuratezza diagnostica di molti esami SPECT [5] after 3-4 months, opted for definitive histological characterization rather than long-term follow-up.
Results
Of the 23 SPNs detected with CT, 11 were positive at scintigraphy and 12 were negative. Among the positive nodules, ten were found to be malignant by subsequent histological examination (size range: 0.8-2 cm) ( Fig. 1) : seven adenocarcinomas, one squamous cell carcinoma, one undifferentiated large cell carcinoma and one myeloma metastasis. There was one false positive, which histology demonstrated to be a giant cell granuloma. Of the 12 negative nodules (size range: 0.8-2 cm), five were related to fibrosis, three were hamartomas (Figs. 2 and 3) and three were granulomas. There was one false negative that was found to be an adenocarcinoma. The smallest lesion (0.8 cm), this adenocarcinoma, measured 1 cm at CT followup after 3 months, with a significant increase in volume and therefore suspicious for malignancy. Table 1 summarises the characteristics of the 23 patients in our study. In particular, the nodules examined were grouped based on well-known differential criteria used with CT. CT indicators of suspected benignity are well-defined contour, nonspiculated margins, fat tissue or calcification in more than 10% of the nodule and contrast enhancement <20 HU. CT indicators of suspected malignancy are blurred contour, spiculated margins, eccentric microcalcifications and contrast enhancement >20 HU.
Nodules were considered "doubtful as to benignity or malignancy" when they showed a prevalence of no more than two criteria whereas they were considered "indeterminate" when they displayed no prevalence of any of the classification criteria.
On the basis of the correlation between the scintigraphic and histological results, the Sestamibi SPECT-CT scan had 90.9 % sensitivity (Se), 91.6 % specificity (Sp), diagnostic accuracy of 91.3 % with positive predictive value (PPV) of 90.9 % and negative predictive value (NPV) of 91.6 % ( Table 2) .
In evaluating the scintigraphic scan, the simultaneous CT acquisition was always decisive in identifying nodular lesions with no uptake and contributed to the differential diagnosis in nodules with uptake located in perihepatic sites. SPECT acquisition alone without the aid of the anatomical CT images was decisive in all enhancing lung lesions other than those with perihepatic distribution. The CT scan with volumetric evaluation after 3-4 months showed absolute concordance with the histological findings ( Table 3) .
Discussion
Conventional chest radiography, the first-line diagnostic tool in all lung diseases, is not sufficiently sensitive or specific to ensure early diagnosis [10] . 
I pazienti portatori di noduli non captanti alla tomoscinti-
grafia sono stati sottoposti ad un nuovo controllo TC a di
Fig. 1a SPECT polmonare con Tc-99m Sestamibi in un uomo di 71 anni. È evidente una iperfissazione del radiofarmaco in corrispondenza del nodulo (20 mm). b TC dello stesso paziente che dimostra la presenza di una formazione nodulare localizzata nel lobo inferiore di destra. c Ricostruzione 3D. Dopo l'asportazione chirurgica il referto istologico ha confermato la natura maligna della lesione (carcinoma anaplastico).
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Diagnostic investigation based on standard chest radiography and sputum cytology failed to deliver the expected results in reducing mortality [11] [12] [13] .
Over the last few years, the concept of early diagnosis of lung cancer has been reconsidered as a following the encouraging results obtained with multidetector computed tomography (MDCT) [8, 14, 15] and the use complementary nuclear medicine methods. A solitary pulmonary nodule is defined as a rounded intraparenchymal opacity that is moderately well delimited, with a maximum diameter less than 3 cm [1] . CT differentiation of benign and malignant lesions is based on qualitative (nodule morphology) and quantitative (density, postcontrast enhancement characteristics, and le- 
Fig. 3a Uomo di 63 anni con esame SPECT negativo per iperaccumoli focali del radiotracciante. b Ricostruzione con algoritmo MIP che evidenzia un nodulo juxta-vascolare (amartoma).
sion growth rate) criteria. In particular, the absence of growth over at least 2 years is a reliable indicator of benignity [16] . The use of 'doubling time', which for spherical le- 
Discussione
Il convenzionale esame radiografico del torace, primo ed essenziale momento diagnostico per tutta la patologia polmonare, non si è dimostrato sufficientemente sensibile e specifico per assicurare una diagnosi precoce [10] . In passato, esami diagnostici basati sulla radiografia standard del torace e sull'esame citologico dell'escreato non hanno dato i risultati sperati nella riduzione della mortalità [11] [12] [13] . Negli ultimi anni si sta assistendo ad una profonda revisione del concetto di diagnosi precoce del cancro del polmone grazie agli incoraggianti risultati ottenuti con la tomografia computerizzata multistrato [8, 14, 15] , ed a tecniche complementari di medicina nucleare. Un NPS è definito come una opacità rotondeggiante intraparenchimale moderatamente ben delimitata con diametro massimo inferiore a 3 cm [1] . Nella differenziazione tra lesioni benigne e maligne in TC sono stati individuati criteri qualitativi, basati sulla morfologia del nodulo e quantitativi, rappresentati dalla densità, caratteristiche di enhancement dopo somministrazione di MdC organoiodato e dalla velocità di crescita della lesione nei casi sottoposti a controllo. In particolare l'assenza di crescita in un periodo di almeno 2 anni è un indicatore attendibile di benignità [16] . [18] (Fig. 4) . Il Tc-99m Sesta- cause they progress so slowly that patients never develop symptoms (type-II pseudodiseases) [17] . An SPN growing at such a rate that its volume-doubling time ranges from 30 to 450 days needs to be further investigated as it is suspicious for malignancy.
The use of automatic segmentation software (ALA) allows, with high accuracy and repeatability, the calculation of volume changes of the SPN in a patient assessed at different times and the significance of the nodule's growth [18] (Fig. 4) . Tc-99m Sestamibi is a radiopharmaceutical usually employed in the study of myocardial perfusion, which has also shown to be effective in cancer diagnostics. The mechanism through which the uptake occurs in cancer cells is still uncertain, and some studies [19] have suggested a role for the negative potential of cell and mitochondrial membranes, passive diffusion, and the lipophilic nature of methoxyisobutyl isonitrile (MIBI). Tc-99m Sestamibi has therefore been used as an 'oncotropic' radiopharmaceutical in the study of various types of cancer, including lung cancer [20] . In agreement with the literature [21, 22] , in all cases examined and subsequently subjected to histopathology, the use of SPECT with Tc-99m Sestamibi often provided support for radiological suspicion, but in selected highly suspicious cases, it prompted surgical excision rather than follow-up. The results suggest, consistent with the literature data [21, 22] , that Sestamibi has a high specificity in the identification of malignant lung lesions.
Although our preliminary data are based on a small case series and require confirmation by larger studies, they suggest that SPECT-CT can detect true positive cases at an early stage. Therefore, the possible inclusion of scintigraphy in the characterisation of SPNs might lead to CT being reserved for the follow-up of scintigraphically negative lesions only. With regard to sensitivity, SPECT yielded one false negative result, in an 8-mm lesion (the smallest in our series).
However, even biological factors such as cancer aggressiveness and the possible presence of multidrug resistance may affect results. The mechanism for the uptake of Tc-99m Sestamibi -a lipophilic cation that is taken up by cancer cells -is related to regional blood flow and to the activity of mitochondria, where it is almost exclusively concentrated [23, 20] . It has also been observed that cancer cells, characterised by chemoresistance, show a rapid washout of Tc-99m Sestamibi, which is linked to increased expression of certain membrane P-glycoproteins [24, 25] .
The main benefit of SPECT-CT fusion imaging was, in our experience, the correct characterisation of perihepatic lesions affected by the normal uptake of the radiopharmaceutical by the liver. The clinical application of SPECT-CT to cancer diagnostics proved to be very useful in preliminary studies published in the literature [26] . Fusion of functional and anatomical images provides accurate localisation of scintigraphic findings, with significant improvement in diagnostic accuracy of the SPECT scans. Our work, although based on a limited number of patients, confirms preliminary results on the potential of this new technique in the differentiation of lung lesions with lipophilic cationic radiopharmaceuticals based on technetium [5] . The use of this radiotracer would also assist in cost-benefit decision making for pamibi è un radiofarmaco impiegato solitamente nello studio della perfusione miocardica, ma dimostratosi efficace nella diagnostica oncologica. Il meccanismo attraverso il quale avviene l'up-take nella cellula neoplastica è ancora incerto ed alcuni studi [19] suggeriscono il ruolo del potenziale negativo delle membrane cellulari e mitocondriali, della diffusione passiva, e della natura lipofilica del MIBI. In virtù di questo il Tc-99m Sestamibi è stato utilizzato come radiofarmaco "oncotropo" per la studio di diverse neoplasie, incluso il tumore polmonare [20] . Nell'ambito del nostro studio l'applicazione della SPECT-TC con Tc-99m Sestamibi, sulla base di precedenti in letteratura [21, 22] [23, 20] . È stato poi osservato che nelle cellule neoplastiche, caratterizzate da chemioresistenza, si ha un rapido wash-out del Tc-99m Sestamibi, legato ad un'aumentata espressione di alcune P-glicoproteine di membrana [24, 25] . Il vantaggio più importante della fusione delle immagini SPECT-TC, nella nostra esperienza, si è avuto nella corretta caratterizzazione delle lesioni peri-epatiche, condizionate dal normale up-take del radiofarmaco da parte del fegato. L'impiego clinico della SPECT-TC in diagnostica oncologica si è rivelato molto utile nelle esperienze preliminari pubblicate in letteratura [26] . Infatti la fusione delle immagini funzionali con quelle anatomiche, permette una precisa localizzazione dei reperti scintigrafici, con un importante miglioramento dell'accuratezza diagnostica degli esami SPECT. Il nostro lavoro, anche se basato su un numero non elevato di pazienti, conferma le acquisizioni preliminari circa le potenzialità di questa nuova tecnica nella diagnostica differenziale delle lesioni polmonari con radiofarmaci cationici lipofilici tecneziati [5] . L'utilizzo di questo radiotracciante sarebbe inoltre di ausilio nell'ottica decisionale costo-beneficio, nei pazienti che, per la compromessa funzionalità cardio-polmonare, risulterebbero ad alto rischio per una toracotomia. Altro aspetto non trascurabile è la maggiore disponibilità sul ter-tients with impaired cardiopulmonary function and ineligible for thoracotomy. Another important aspect is that SPECT is more widely available and less expensive than positron emission tomography-fluorodeoxyglucose (PET-FDG), an examination that is sensitive and specific in diagnosis and staging of lung cancer [27, 28] but currently limited by its cost and poor availability. PET-FDG, however, has an accuracy of 90% and sensitivity and specificity of 91% and 68%, respectively, in the differential diagnosis of SPNs [29] .
Conclusions
In conclusion, the joint use of CT and Sestamibi SPECT in managing a patient with an SPN might represent another diagnostic tool in the differentiation of benign and malignant lung lesions in the future.
ritorio delle apparecchiature ed il basso costo dell'esame, se confrontato con la PET-FDG, esame dimostratosi sensibile e specifico nella diagnosi e nella stadiazione delle neoplasie polmonari [27, 28] , ma attualmente limitato dai costi e dalla scarsa reperibilità su territorio. La PET-FDG, comunque, dimostra nella diagnosi differenziale del NPS una accuratezza del 90%, con una sensibilità ed una specificità del 91% e 68% rispettivamente [29] .
Conclusioni
In conclusione, l'utilizzo consensuale della TC e della SPECT con Sestamibi nella gestione del paziente portatore di un NPS potrebbe rappresentare in futuro un ulteriore strumento diagnostico nell'iter differenziale tra lesioni polmonari benigne e maligne.
